Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05832229 · ClinicalTrials.gov registry record · Phase 2

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

A Phase 2 study of Cirrhosis and Cirrhosis, Liver, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Recruiting
Registry status
Phase 2
Development phase
256
Enrollment target
13
Study locations

NCT05832229 is a Phase 2 study of Cirrhosis and Cirrhosis, Liver that is actively recruiting participants, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 256 participants, below the 90,404-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The trial reports 13 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05832229, a Phase 2 study of Cirrhosis and Cirrhosis, Liver, is actively recruiting participants, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

RECRUITING
Registry status
Phase 2
Development phase
256 participants
Enrollment target
13
Study locations

Study Summary

This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.

Conditions Studied

Cirrhosis Cirrhosis, Liver Cirrhosis Early Cirrhosis Due to Hepatitis B Cirrhosis Advanced Cirrhosis Infectious Cirrhosis Alcoholic Cirrhosis Due to Hepatitis C

Interventions

  • DRUG Rosuvastatin

Study Locations (13)

California

  • University of California San Diego NAFLD Research Center - La Jolla
  • Keck Medical Center of USC - Los Angeles
  • LAC + USC Medical Center - Los Angeles
  • UCSF/Zuckerberg San Francisco General Hospital and Trauma Center - San Francisco
  • UCSF Medical Center - San Francisco

New York

  • New York Presbyterian/Weill Cornell - New York
  • Columbia University Iriving School of Medicine - New York

Florida

  • University of Miami Health System - Miami

Michigan

  • University of Michigan - Ann Arbor

Minnesota

  • Mayo Clinic - Rochester

North Carolina

  • Duke Liver Center - Durham

Ohio

  • Cleveland Clinic - Cleveland

Virginia

  • Virginia Commonwealth University - Richmond

Trial Details

FieldValue
Enrollment Target 256 participants
Start Date 2023-12-07
Est. Completion 2029-08-31
Phase Phase 2

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

490 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05832229

The ClinicalTrials.gov registry entry for NCT05832229 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90,404-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Cirrhosis appearing as the primary indexed condition, and to 1 intervention - of which Rosuvastatin is the first listed.

NCT05832229 reports 13 study locations spanning 8 distinct geographic areas - top geographies include California, New York, Florida.

Frequently Asked Questions

What is clinical trial NCT05832229 about?

NCT05832229 is a clinical study titled "Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States". This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.

What is the current status of trial NCT05832229?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 256 participants. The study started on 2023-12-07. Estimated completion is 2029-08-31.

What conditions does trial NCT05832229 study?

This clinical trial studies the following conditions: Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced.

What interventions are being tested in trial NCT05832229?

The interventions under investigation include: Rosuvastatin (DRUG).

Who is sponsoring clinical trial NCT05832229?

This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05832229 being conducted?

This trial has 13 study locations across California, Florida, Michigan, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cirrhosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cirrhosis

All registered trials for this condition

Cirrhosis, Liver

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.